Trial Profile
A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- Sponsors Janssen Research & Development; TARIS Biomedical
- 08 Apr 2023 Results from phase 1 study published in the Journal of Urology
- 17 Oct 2022 Status changed from active, no longer recruiting to completed.
- 02 Dec 2021 Planned End Date changed from 22 Jul 2022 to 30 Sep 2022.